The Trump administration has canceled a significant contract with Moderna, aimed at developing a vaccine for the H5N1 avian influenza, reversing a previous agreement made during the Biden administration. This decision raises concerns about future vaccine development and pandemic preparedness.
1. Contract Cancellation:
• Trump's administration terminated a $766 million contract with Moderna for an mRNA-based bird flu vaccine.
• The cancellation was based on a review by the U. S. Department of Health and Human Services (HHS) which determined the project did not meet necessary scientific standards.
2. Impact on Moderna:
• Moderna's CEO Stéphane Bancel expressed that the loss of funding introduces uncertainty to the company's bird flu program.
• The cancellation has come at a challenging time for Moderna as it is awaiting a decision on its next-generation COVID-19 vaccine and has faced declining demand for its COVID-19 shots.
3. Regulatory and Market Challenges:
• Moderna has also recently withdrawn its application for a combined flu-COVID-19 vaccine due to discussions with the FDA, planning to resubmit later with more data.
• This signals broader regulatory challenges for mRNA vaccine technologies.
4. Concerns about H5N1 Virus:
• The H5N1 virus has posed threats to birds, cattle, and sporadically to humans, raising fears of potential human transmission.
The cancellation of the contract reflects a shift in federal priorities regarding vaccine funding under the Trump administration. While some view this as an essential move for scientific scrutiny, others worry it may weaken the U. S. response to future pandemics. The ongoing discussion around mRNA vaccines continues to shape the future of public health and biotechnology.
https://www.naturalnews.com/2025-05-30-trump-admin-yanks-700million-funding-from-moderna.html
No comments:
Post a Comment